Navigation Links
Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
Date:11/23/2007

PRINCETON, N.J., and PARIS, Nov. 23 /PRNewswire-FirstCall/ -- Bristol- Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported today that they are terminating their license agreement for the development of vinflunine, a chemotherapy agent under investigation for the treatment of advanced or metastatic bladder cancer and other tumor types. Vinflunine was developed by Pierre Fabre Medicament and licensed to Bristol-Myers Squibb in 2004 for specific territories. Based on a review of the clinical development program and the decision not to file a new drug application for bladder cancer in the United States, coupled with an analysis of Bristol-Myers Squibb's Research & Development priorities, the companies have jointly decided that all rights licensed to Bristol-Myers Squibb for vinflunine will be returned to Pierre Fabre Medicament.

"In Europe, Pierre Fabre Medicament intend to continue discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008," said P. Hurteloup, General Manager of Pierre Fabre Medicament Oncology Division. "We also are considering a range of further development options, including pursuing the product on a worldwide basis for the treatment of a number of cancers."

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

Pierre Fabre Medicament is a French private group dedicated to consumers and patients from health to beauty.


'/>"/>
SOURCE Bristol-Myers Squibb Company; Pierre Fabre Medicament
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Bristol-Myers Squibb to Acquire Adnexus Therapeutics
3. Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases
4. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
5. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
6. CardioDynamics Provides 2007 Shareholder Meeting Update
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
9. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
10. ZymoGenetics Will Hold Conference Call Today at 5:00 p.m. Eastern Time to Provide Update on rThrombin
11. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/11/2017)... Wayne. NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a ... rinse one eye at a time. So which eye do you rinse first if a ... you have Plum Duo Eye Wash with its unique dual eye piece. , ...
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. Representatives of ... award for Excellence in Volunteer Experience from US2020. , US2020’s mission is to ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
Breaking Biology News(10 mins):